Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltiorrhiza

Phytomedicine

Volumn 21, Issue 11, 2014, Pages 1264-1272

  Hu, Tao ^a   To, Kenneth K W ^b   Wang, Lin ^a   Zhang, Lin ^a   Lu, Lan ^a   Shen, Jing ^a   Chan, Ruby L Y ^a   Li, Mingxing ^a   Yeung, John H K ^a   Cho, Chi Hin ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

Cryptotanshinone; Dihydrotanshinone; Multidrug resistance; P glycoprotein; Salvia miltiorrhiza

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CRYPTOTANSHINONE; DIGOXIN; DIHYDROTANSHINONE; DOXORUBICIN; IRINOTECAN; MESSENGER RNA; MILTIRONE; MULTIDRUG RESISTANCE PROTEIN; TANSHINONE; TANSHINONE I; TANSHINONE IIA; UNCLASSIFIED DRUG; VERAPAMIL; 15,16-DIHYDROTANSHINONE I; ABCB1 PROTEIN, HUMAN; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; HERBACEOUS AGENT; PHENANTHRENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATPASE ACTIVITY ASSAY; CACO 2 CELL LINE; CANCER CELL; CELL VIABILITY; CHINESE MEDICINE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TRANSPORT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; LABORATORY; MTT ASSAY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVIA MILTIORRHIZA; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CACO-2 CELLS; CAMPTOTHECIN; DIGOXIN; DITERPENES, ABIETANE; DOXORUBICIN; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEINS; PHENANTHRENES; SALVIA MILTIORRHIZA;

EID: 84906724437     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2014.06.013     Document Type: Article

References (18)

1. T. Bansal, G. Mishra, M. Jaggi, R.K. Khar, and S. Talegaonkar Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats Eur. J. Pharm. Sci. 36 2009 580 590
2. I. Bosch, and J.M. Croop P-glycoprotein structure and evolutionary homologies Cytotechnology 27 1998 1 30 (Pubitemid 29025458)
3. R.A. Darby, R. Callaghan, and R.M. McMahon P-glycoprotein inhibition: the past, the present and the future Curr. Drug Metab. 12 2011 722 731
4. K.S. Fenner, M.D. Troutman, S. Kempshall, J.A. Cook, J.A. Ware, D.A. Smith, and C.A. Lee Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug Clin. Pharmacol. Ther. 85 2009 173 181
5. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, and L. Zhang Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
6. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58 (Pubitemid 37328807)
7. S.M. Huang, R. Temple, D.C. Throckmorton, and L.J. Lesko Drug interaction studies: study design, data analysis, and implications for dosing and labeling Clin. Pharmacol. Ther. 81 2007 298 304 (Pubitemid 46174829)
8. I. Hubatsch, E.G. Ragnarsson, and P. Artursson Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers Nat. Protoc. 2 2007 2111 2119 (Pubitemid 351565848)
9. J. Hughes, and A. Crowe Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics J. Pharmacol. Sci. 113 2010 315 324
10. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman CA Cancer J. Clin. 61 2011 69 90
11. A. Palmeira, E. Sousa, M.H. Vasconcelos, and M.M. Pinto Three decades of P-gp inhibitors: skimming through several generations and scaffolds Curr. Med. Chem. 19 2012 1946 2025
12. A. Persidis Cancer multidrug resistance Nat. Biotechnol. 17 1999 94 95 (Pubitemid 29037219)
13. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234 (Pubitemid 43336035)
14. K.K. To, S.X. Ren, C.C. Wong, and C.H. Cho Reversal of ABCG2-mediated multidrug resistance by human cathelicidin and its analogs in cancer cells Peptides 40 2013 13 21
15. W.Y. Wu, and Y.P. Wang Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components Acta Pharmacol. Sin. 33 2012 1119 1130
16. W. Zhang, Y. Han, S.L. Lim, and L.Y. Lim Dietary regulation of P-gp function and expression Expert Opin. Drug Metab. Toxicol. 5 2009 789 801
17. L. Zhou, Z. Zuo, and M.S. Chow Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use J. Clin. Pharmacol. 45 2005 1345 1359 (Pubitemid 41643896)
18. S. Zhou, L.Y. Lim, and B. Chowbay Herbal modulation of P-glycoprotein Drug Metab. Rev. 36 2004 57 104 (Pubitemid 38387835)